

Drug Monograph

Drug Name: **Myrbetriq® (mirabegron) extended-release, oral**
 Drug Class: **suspension**
Renal and Genitourinary: Urinary Tract Antispasmodics
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Myrbetriq is now available in an extended-release oral suspension containing 8 mg/ml. It joins extended-release tablets in 25 mg and 50 mg.

Manufacturer: Manufactured by: Astellas Pharma US, Inc., Northbrook, IL 60062.

Indications: Myrbetriq granules for oral suspension is indicated for the treatment of Neurogenic Detrusor Overactivity (NDO) in patients ≥3 years.

Costs: \$415.80 per 180 ml (30 day supply at 6 ml per day). Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD
 Date: September 1, 2021